BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA, Zuo M, Yadav V, Wang J, Woodard W, Lezak SP, Lugogo NL, Smith SA, Morrissey JH, Kanthi Y, Knight JS. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020;12:eabd3876. [PMID: 33139519 DOI: 10.1126/scitranslmed.abd3876] [Cited by in Crossref: 136] [Cited by in F6Publishing: 139] [Article Influence: 68.0] [Reference Citation Analysis]
Number Citing Articles
1 Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. J Autoimmun 2021;122:102685. [PMID: 34174723 DOI: 10.1016/j.jaut.2021.102685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
3 Nusshag C, Morath C, Speer C, Kaelble F, Zeier M, Boxberger M, Schulze-Schleithoff E, Fiedler MO, Weigand MA, Merle U. Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience. Crit Care Explor 2021;3:e0517. [PMID: 34476404 DOI: 10.1097/CCE.0000000000000517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Erber J, Wiessner JR, Huberle C, Schneider J, Mijočević H, von Bomhard D, Luppa P, Schmid RM, Rasch S, Lahmer T. Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 - A case series. Transfus Apher Sci 2021;:103278. [PMID: 34548246 DOI: 10.1016/j.transci.2021.103278] [Reference Citation Analysis]
5 Goshua G, Butt A, Lee AI. Immunothrombosis: a COVID-19 concerto. Br J Haematol 2021;194:491-3. [PMID: 34114208 DOI: 10.1111/bjh.17666] [Reference Citation Analysis]
6 Elbadawi A, Elgendy IY, Joseph D, Eze-Nliam C, Rampersad P, Ouma G, Bhandari R, Kirksey L, Chaudhury P, Chung MK, Kalra A, Mehta N, Bartholomew JR, Sahai A, Svensson LG, Cameron SJ. Racial Differences and In-Hospital Outcomes Among Hospitalized Patients with COVID-19. J Racial Ethn Health Disparities 2021. [PMID: 34506011 DOI: 10.1007/s40615-021-01140-2] [Reference Citation Analysis]
7 Favaloro EJ, Henry BM, Lippi G. COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check? Semin Thromb Hemost 2021. [PMID: 34130340 DOI: 10.1055/s-0041-1728832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Emadi-Baygi M, Ehsanifard M, Afrashtehpour N, Norouzi M, Joz-Abbasalian Z. Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. Front Immunol 2021;12:778913. [PMID: 34912345 DOI: 10.3389/fimmu.2021.778913] [Reference Citation Analysis]
9 Hottz ED, Bozza PT. Platelet‐leukocyte interactions in COVID‐19: Contributions to hypercoagulability, inflammation, and disease severity. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12709] [Reference Citation Analysis]
10 Zhou Z, Zhou X, Cheng L, Wen L, An T, Gao H, Deng H, Yan Q, Zhang X, Li Y, Liao Y, Chen XZ, Nie B, Cheng J, Deng G, Wang S, Li J, Yin H, Zhang M, Cai L, Zheng L, Li M, Jones B, Chen L, Abdollahi A, Zhou M, Zhou PK, Zhou C. Machine learning algorithms utilizing blood parameters enable early detection of immunethrombotic dysregulation in COVID-19. Clin Transl Med 2021;11:e523. [PMID: 34586734 DOI: 10.1002/ctm2.523] [Reference Citation Analysis]
11 Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, Li SY, Li Y, He YW. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Sci China Life Sci 2020;63:1833-49. [PMID: 33355886 DOI: 10.1007/s11427-020-1859-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Serrano M, Espinosa G, Lalueza A, Bravo-Gallego LY, Diaz-Simón R, Garcinuño S, Gil-Etayo J, Moises J, Naranjo L, Prieto-González S, Ruiz-Ortiz E, Sánchez B, Moreno-Castaño AB, Díaz-Pedroche C, Viñas-Gomis O, Cervera R, Serrano A; APS-COVID 19 Study Group/European Forum on Antiphospholipid Antibodies. Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019. ACR Open Rheumatol 2021;3:267-76. [PMID: 33738987 DOI: 10.1002/acr2.11245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Zuo Y, Yalavarthi S, Navaz SA, Hoy CK, Harbaugh A, Gockman K, Zuo M, Madison JA, Shi H, Kanthi Y, Knight JS. Autoantibodies stabilize neutrophil extracellular traps in COVID-19. JCI Insight 2021;6:150111. [PMID: 34166229 DOI: 10.1172/jci.insight.150111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy 2021. [PMID: 34582050 DOI: 10.1111/all.15112] [Reference Citation Analysis]
15 Fox SE, Heide RSV. COVID-19: The Heart of the Matter-Pathological Changes and a Proposed Mechanism. J Cardiovasc Pharmacol Ther 2021;26:217-24. [PMID: 33703938 DOI: 10.1177/1074248421995356] [Reference Citation Analysis]
16 Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Bautista JA, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-Ramirez J, Tang AF, Wenger M, Assenzio M, Yuan Y, Krone M, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Sauceda JA, Gandhi M, Hsue PY, Henrich TJ, Deeks SG, Martin JN. Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv 2021:2021. [PMID: 33758895 DOI: 10.1101/2021.03.11.21252311] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ryu JK, Sozmen EG, Dixit K, Montano M, Matsui Y, Liu Y, Helmy E, Deerinck TJ, Yan Z, Schuck R, Acevedo RM, Spencer CM, Thomas R, Pico AR, Zamvil SS, Lynch KL, Ellisman MH, Greene WC, Akassoglou K. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. bioRxiv 2021:2021. [PMID: 34671772 DOI: 10.1101/2021.10.12.464152] [Reference Citation Analysis]
18 Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-ramirez J, Tang AF, Wenger MA, Assenzio MT, Yuan Y, Krone MR, Rutishauser RL, Rodriguez-barraquer I, Greenhouse B, Sauceda JA, Gandhi M, Scheffler AW, Hsue PY, Henrich TJ, Deeks SG, Martin JN. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases 2022;9:ofab640. [DOI: 10.1093/ofid/ofab640] [Reference Citation Analysis]
19 Dieudonné Y, Guffroy A, Poindron V, Sprauel PS, Martin T, Korganow AS, Gies V. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmun Rev 2021;20:102798. [PMID: 33722752 DOI: 10.1016/j.autrev.2021.102798] [Reference Citation Analysis]
20 Izquierdo-pujol J, Moron-lopez S, Dalmau J, Gonzalez-aumatell A, Carreras-abad C, Mendez M, Rodrigo C, Martinez-picado J. Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. Front Pediatr 2022;10:894204. [DOI: 10.3389/fped.2022.894204] [Reference Citation Analysis]
21 Cappadona C, Paraboschi EM, Ziliotto N, Bottaro S, Rimoldi V, Gerussi A, Azimonti A, Brenna D, Brunati A, Cameroni C, Campanaro G, Carloni F, Cavadini G, Ciravegna M, Composto A, Converso G, Corbella P, D'Eugenio D, Dal Rì G, Di Giorgio SM, Grondelli MC, Guerrera L, Laffoucriere G, Lando B, Lopedote L, Maizza B, Marconi E, Mariola C, Matronola GM, Menga LM, Montorsi G, Papatolo A, Patti R, Profeta L, Rebasti V, Smidili A, Tarchi SM, Tartaglia FC, Tettamanzi G, Tinelli E, Stuani R, Bolchini C, Pattini L, Invernizzi P, Degenhardt F, Franke A, Duga S, Asselta R. MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity. J Pers Med 2021;11:1166. [PMID: 34834519 DOI: 10.3390/jpm11111166] [Reference Citation Analysis]
22 Tan J, Anderson DE, Rathore APS, O'Neill A, Mantri CK, Saron WAA, Lee C, Cui CW, Kang AEZ, Foo R, Kalimuddin S, Low JG, Ho L, Tambyah P, Burke TW, Woods CW, Chan KR, Karhausen J, John ALS. Signatures of mast cell activation are associated with severe COVID-19. medRxiv 2021:2021. [PMID: 34100020 DOI: 10.1101/2021.05.31.21255594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vianello A, Del Turco S, Babboni S, Silvestrini B, Ragusa R, Caselli C, Melani L, Fanucci L, Basta G. The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity? Biomedicines 2021;9:710. [PMID: 34201505 DOI: 10.3390/biomedicines9070710] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Haberman RH, Jaros BD, Scher JU. Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. Curr Opin Rheumatol 2021;33:409-11. [PMID: 34175865 DOI: 10.1097/BOR.0000000000000813] [Reference Citation Analysis]
25 Nath A. Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Continuum (Minneap Minn) 2021;27:1051-65. [PMID: 34623104 DOI: 10.1212/CON.0000000000000992] [Reference Citation Analysis]
26 Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021;53:737-54. [PMID: 34024217 DOI: 10.1080/23744235.2021.1924397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
27 Francistiová L, Klepe A, Curley G, Gulya K, Dinnyés A, Filkor K. Cellular and Molecular Effects of SARS-CoV-2 Linking Lung Infection to the Brain. Front Immunol 2021;12:730088. [PMID: 34484241 DOI: 10.3389/fimmu.2021.730088] [Reference Citation Analysis]
28 Shi H, Zuo Y, Navaz S, Harbaugh A, Hoy C, Gandhi AA, Sule G, Yalavarthi S, Gockman K, Madison JA, Wang J, Zuo M, Shi Y, Maile MD, Knight JS, Kanthi Y. Endothelial cell-activating antibodies in COVID-19. medRxiv 2021:2021. [PMID: 33501469 DOI: 10.1101/2021.01.18.21250041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
29 Winchester N, Calabrese C, Calabrese LH. The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding? Pathog Immun 2021;6:31-54. [PMID: 33969248 DOI: 10.20411/pai.v6i1.417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Tung ML, Tan B, Cherian R, Chandra B. Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. Rheumatol Adv Pract 2021;5:rkaa081. [PMID: 33615129 DOI: 10.1093/rap/rkaa081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. J Mol Cell Cardiol 2021;164:69-82. [PMID: 34838588 DOI: 10.1016/j.yjmcc.2021.11.010] [Reference Citation Analysis]
32 Gil-Etayo FJ, Garcinuño S, Lalueza A, Díaz-Simón R, García-Reyne A, Pleguezuelo DE, Cabrera-Marante O, Rodriguez-Frias EA, Perez-Rivilla A, Serrano M, Serrano A. Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor. Biomedicines 2021;9:899. [PMID: 34440103 DOI: 10.3390/biomedicines9080899] [Reference Citation Analysis]
33 Walczak P, Janowski M. The COVID-19 Menace. Glob Chall 2021;:2100004. [PMID: 34178377 DOI: 10.1002/gch2.202100004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, Barman L, Bennett K, Chakraborty S, Chang I, Cheung P, Chinthrajah S, Dhingra S, Do E, Finck A, Gaano A, Geßner R, Giannini HM, Gonzalez J, Greib S, Gündisch M, Hsu AR, Kuo A, Manohar M, Mao R, Neeli I, Neubauer A, Oniyide O, Powell AE, Puri R, Renz H, Schapiro J, Weidenbacher PA, Wittman R, Ahuja N, Chung HR, Jagannathan P, James JA, Kim PS, Meyer NJ, Nadeau KC, Radic M, Robinson WH, Singh U, Wang TT, Wherry EJ, Skevaki C, Luning Prak ET, Utz PJ. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021;12:5417. [PMID: 34521836 DOI: 10.1038/s41467-021-25509-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Emmenegger M, Kumar SS, Emmenegger V, Malinauskas T, Buettner T, Rose L, Schierack P, Sprinzl MF, Sommer CJ, Lackner KJ, Aguzzi A, Roggenbuck D, Frauenknecht KBM. Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins. PLoS Pathog 2021;17:e1010118. [PMID: 34860860 DOI: 10.1371/journal.ppat.1010118] [Reference Citation Analysis]
36 Hollerbach A, Müller-Calleja N, Pedrosa D, Canisius A, Sprinzl MF, Falter T, Rossmann H, Bodenstein M, Werner C, Sagoschen I, Münzel T, Schreiner O, Sivanathan V, Reuter M, Niermann J, Galle PR, Teyton L, Ruf W, Lackner KJ. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost 2021;19:2335-47. [PMID: 34242469 DOI: 10.1111/jth.15455] [Reference Citation Analysis]
37 Liu K, Song B, Palacios IF, Inglessis-Azuaje I, Lo EH, Xu Y, Buonanno FS, Ning M. Reply: Shouldn't Patients With Paradoxical Emboli and Thrombophilia Be Given Anticoagulant Agents? JACC Cardiovasc Interv 2021;14:583-4. [PMID: 33663787 DOI: 10.1016/j.jcin.2021.01.002] [Reference Citation Analysis]
38 Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science 2022;375:1122-7. [PMID: 35271343 DOI: 10.1126/science.abm8108] [Reference Citation Analysis]
39 Moody R, Wilson K, Flanagan KL, Jaworowski A, Plebanski M. Adaptive Immunity and the Risk of Autoreactivity in COVID-19. Int J Mol Sci 2021;22:8965. [PMID: 34445670 DOI: 10.3390/ijms22168965] [Reference Citation Analysis]
40 Andreano E, Rappuoli R. Immunodominant antibody germlines in COVID-19. J Exp Med 2021;218:e20210281. [PMID: 33656515 DOI: 10.1084/jem.20210281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
41 Batista CM, Foti L. Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. Int Immunopharmacol 2021;99:108036. [PMID: 34371330 DOI: 10.1016/j.intimp.2021.108036] [Reference Citation Analysis]
42 Siscel J, Short M, Flynn B. Understanding ST-Elevation Myocardial Infarction in COVID-19: The Marriage of Bench Work and Big Data. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00474-2. [PMID: 34218995 DOI: 10.1053/j.jvca.2021.06.002] [Reference Citation Analysis]
43 Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Rev Clin Immunol 2021;17:431-43. [PMID: 33750254 DOI: 10.1080/1744666X.2021.1905526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
44 de Campos-Mata L, Tejedor Vaquero S, Tachó-Piñot R, Piñero J, Grasset EK, Arrieta Aldea I, Rodrigo Melero N, Carolis C, Horcajada JP, Cerutti A, Villar-García J, Magri G. SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B-cell responses. Clin Transl Immunology 2021;10:e1339. [PMID: 34504693 DOI: 10.1002/cti2.1339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV 3rd, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res 2021;128:1214-36. [PMID: 33856918 DOI: 10.1161/CIRCRESAHA.121.317997] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
46 Jones OY, Yeralan S. Is Long COVID a State of Systemic Pericyte Disarray? JCM 2022;11:572. [DOI: 10.3390/jcm11030572] [Reference Citation Analysis]
47 Chalayer E, Gramont B, Zekre F, Goguyer-Deschaumes R, Waeckel L, Grange L, Paul S, Chung AW, Killian M. Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseases. Autoimmun Rev 2021;21:103016. [PMID: 34915182 DOI: 10.1016/j.autrev.2021.103016] [Reference Citation Analysis]
48 Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open 2021;7:e001580. [PMID: 33958439 DOI: 10.1136/rmdopen-2021-001580] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
49 Nicosia RF, Ligresti G, Caporarello N, Akilesh S, Ribatti D. COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury. Am J Pathol 2021;191:1374-84. [PMID: 34033751 DOI: 10.1016/j.ajpath.2021.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
50 Wong AKH, Woodhouse I, Schneider F, Kulpa DA, Silvestri G, Maier CL. Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19. Cell Rep Med 2021;2:100321. [PMID: 34075365 DOI: 10.1016/j.xcrm.2021.100321] [Reference Citation Analysis]
51 Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front Immunol 2021;12:686029. [PMID: 34276671 DOI: 10.3389/fimmu.2021.686029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Nagy E, Infantino M, Bizzaro N, Andreeva H, Bontkes HJ, Bossuyt X, Fabien N, Fischer K, Heijnen IAFM, Herold M, Kozmar A, Kuhi L, López-Hoyos M, Pullerits R, Sousa MJR, Tsirogianni A, Damoiseaux J; European Autoimmunity Standardisation Initiative. The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned. Autoimmun Rev 2021;:102985. [PMID: 34718167 DOI: 10.1016/j.autrev.2021.102985] [Reference Citation Analysis]
53 Neagu M, Constantin C, Surcel M. Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic—Experience and Outlines. IJERPH 2021;18:13173. [DOI: 10.3390/ijerph182413173] [Reference Citation Analysis]
54 Farhadian SF, Seilhean D, Spudich S. Neuropathogenesis of acute coronavirus disease 2019. Curr Opin Neurol 2021;34:417-22. [PMID: 33852526 DOI: 10.1097/WCO.0000000000000944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zimering MB. Severe COVID-19 Pneumonia is Associated with Increased Plasma Immunoglobulin G Agonist Autoantibodies Targeting the 5-Hydroxytryptamine 2A Receptor. Endocrinol Diabetes Metab J 2021;5:1-9. [PMID: 33680365 DOI: 10.31038/EDMJ.2021511] [Reference Citation Analysis]
56 Marik PE, Iglesias J, Varon J, Kory P. A scoping review of the pathophysiology of COVID-19. Int J Immunopathol Pharmacol 2021;35:20587384211048026. [PMID: 34569339 DOI: 10.1177/20587384211048026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Focosi D, Maggi F, Franchini M, Aguzzi A, Lanza M, Mazzoni A, Menichetti F. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect 2021;27:987-92. [PMID: 33878505 DOI: 10.1016/j.cmi.2021.04.003] [Reference Citation Analysis]
58 Zuniga M, Gomes C, Carsons SE, Bender MT, Cotzia P, Miao QR, Lee DC, Rodriguez A. Autoimmunity to Annexin A2 predicts mortality among hospitalised COVID-19 patients. Eur Respir J 2021:2100918. [PMID: 34244321 DOI: 10.1183/13993003.00918-2021] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
59 Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and Myositis: What We Know So Far. Curr Rheumatol Rep 2021;23:63. [PMID: 34216297 DOI: 10.1007/s11926-021-01023-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Hanna EB, Rossen J, Eustes AS, Dayal S. Heavy lone coronary artery thrombosis treated by stent retriever, in the setting of COVID‐19 infection. Cathet Cardio Intervent. [DOI: 10.1002/ccd.30084] [Reference Citation Analysis]
61 Stertz S, Hale BG. Interferon system deficiencies exacerbating severe pandemic virus infections. Trends Microbiol 2021:S0966-842X(21)00060-3. [PMID: 33757684 DOI: 10.1016/j.tim.2021.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
62 Pavoni V, Gianesello L, Horton A. Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon? J Thromb Thrombolysis 2021. [PMID: 33973157 DOI: 10.1007/s11239-021-02470-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kastenhuber ER, Jaimes JA, Johnson JL, Mercadante M, Muecksch F, Weisblum Y, Bram Y, Schwartz RE, Whittaker GR, Cantley LC. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. bioRxiv 2021:2021. [PMID: 33821268 DOI: 10.1101/2021.03.31.437960] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
64 La Cava A. Antiphospholipid antibodies and COVID-19. Autoimmun Rev 2021;20:102910. [PMID: 34303846 DOI: 10.1016/j.autrev.2021.102910] [Reference Citation Analysis]
65 Flores-Pliego A, Miranda J, Vega-Torreblanca S, Valdespino-Vázquez Y, Helguera-Repetto C, Espejel-Nuñez A, Borboa-Olivares H, Espino Y Sosa S, Mateu-Rogell P, León-Juárez M, Ramírez-Santes V, Cardona-Pérez A, Villegas-Mota I, Torres-Torres J, Juárez-Reyes Á, Rizo-Pica T, González RO, González-Mariscal L, Estrada-Gutierrez G. Molecular Insights into the Thrombotic and Microvascular Injury in Placental Endothelium of Women with Mild or Severe COVID-19. Cells 2021;10:364. [PMID: 33578631 DOI: 10.3390/cells10020364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Jevtic SD, Nazy I. The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. Front Immunol 2022;13:807934. [DOI: 10.3389/fimmu.2022.807934] [Reference Citation Analysis]
67 Byttebier G, Belmans L, Alexander M, Saxberg BEH, De Spiegeleer B, De Spiegeleer A, Devreker N, Van Praet JT, Vanhove K, Reybrouck R, Wynendaele E, Fedson DS. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. Hum Vaccin Immunother 2021;17:2841-50. [PMID: 34047686 DOI: 10.1080/21645515.2021.1920271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Vollmer O, Tacquard C, Dieudonné Y, Nespola B, Sattler L, Grunebaum L, Gies V, Radosavljevic M, Kaeuffer C, Hansmann Y, Weber JC, Martin T, Arnaud L, Morel O, Guffroy A, Collange O, Mertes PM, Korganow AS, Delabranche X, Poindron V. Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent. Autoimmun Rev 2021;20:102822. [PMID: 33872769 DOI: 10.1016/j.autrev.2021.102822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
69 [DOI: 10.1101/2021.01.04.21249227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
70 Colling ME, Tourdot BE, Kanthi Y. Inflammation, Infection and Venous Thromboembolism. Circ Res 2021;128:2017-36. [PMID: 34110909 DOI: 10.1161/CIRCRESAHA.121.318225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Gallman AE, Fassett MS. Cutaneous Pathology of COVID-19 as a Window into Immunologic Mechanisms of Disease. Dermatol Clin 2021;39:533-43. [PMID: 34556243 DOI: 10.1016/j.det.2021.05.008] [Reference Citation Analysis]
72 [DOI: 10.1101/2020.12.28.20248807] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Apple AC, Oddi A, Peluso MJ, Asken BM, Henrich TJ, Kelly JD, Pleasure SJ, Deeks SG, Allen IE, Martin JN, Ndhlovu LC, Miller BL, Stephens ML, Hellmuth J. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol 2022. [PMID: 35043593 DOI: 10.1002/acn3.51498] [Reference Citation Analysis]
74 Koch BF. SARS-CoV-2 and human retroelements: a case for molecular mimicry? BMC Genom Data 2022;23:27. [PMID: 35395708 DOI: 10.1186/s12863-022-01040-2] [Reference Citation Analysis]
75 Vo TD, Daoud A, Jeney A, Andacheh I, Behseresht J, Hsu J, Tayyarah M, Slezak J. COVID-19 Related Peripheral Arterial Thrombosis Treated in a Large Health Managed Organization. Annals of Vascular Surgery 2022. [DOI: 10.1016/j.avsg.2022.04.024] [Reference Citation Analysis]
76 Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 2021;18:666-82. [PMID: 33958774 DOI: 10.1038/s41569-021-00552-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
77 Liu T, Dai J, Yang Z, Yu X, Xu Y, Shi X, Wei D, Tang Z, Xu G, Xu W, Liu Y, Shi C, Ni Q, Yang C, Zhang X, Wang X, Chen E, Qu J. Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort. Sci Bull (Beijing) 2021. [PMID: 34336365 DOI: 10.1016/j.scib.2021.07.033] [Reference Citation Analysis]
78 Khan NZ, Chen LY, Lindenbauer A, Pliquett U, Rothe H, Nguyen TH. Label-Free Detection and Characterization of Heparin-Induced Thrombocytopenia (HIT)-like Antibodies. ACS Omega 2021;6:25926-39. [PMID: 34660955 DOI: 10.1021/acsomega.1c02496] [Reference Citation Analysis]
79 Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, Zheng NS, Zhou T, Israelow B, Wong P, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Cruz CD, Farhadian SF, Schulz WL, Grubaugh ND, Ko AI, Iwasaki A, Ring AM; Yale IMPACT Team. Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv 2021:2020. [PMID: 33330894 DOI: 10.1101/2020.12.10.20247205] [Cited by in Crossref: 51] [Cited by in F6Publishing: 10] [Article Influence: 51.0] [Reference Citation Analysis]
80 Sagris D, Papanikolaou A, Kvernland A, Korompoki E, Frontera JA, Troxel AB, Gavriatopoulou M, Milionis H, Lip GYH, Michel P, Yaghi S, Ntaios G. COVID-19 and ischemic stroke. Eur J Neurol 2021. [PMID: 34224187 DOI: 10.1111/ene.15008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Yang Y, Iwasaki A. Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. Curr HIV/AIDS Rep 2021. [PMID: 34843064 DOI: 10.1007/s11904-021-00590-x] [Reference Citation Analysis]
82 Cari L, Alhosseini MN, Fiore P, Pierno S, Pacor S, Bergamo A, Sava G, Nocentini G. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. J Autoimmun 2021;125:102742. [PMID: 34710832 DOI: 10.1016/j.jaut.2021.102742] [Reference Citation Analysis]
83 Schmid A, Petrovic M, Akella K, Pareddy A, Velavan SS. Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19. Int J Vasc Med 2021;2021:6693895. [PMID: 34035963 DOI: 10.1155/2021/6693895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Zhou M, Tan X, Luo P, Xu J, Yin Z, Liao T, Wang S, Wang Z, Jin Y. Changes in glomerular filtration rate and metabolomic differences in severely ill coronavirus disease survivors 3 months after discharge. Biochim Biophys Acta Mol Basis Dis 2022;1868:166289. [PMID: 34656797 DOI: 10.1016/j.bbadis.2021.166289] [Reference Citation Analysis]
85 Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M, Abbate A. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021;21:319-29. [PMID: 33824483 DOI: 10.1038/s41577-021-00536-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 33.0] [Reference Citation Analysis]
86 Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021;232:13-36. [PMID: 33352298 DOI: 10.1016/j.trsl.2020.12.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
87 Sjöwall J, Azharuddin M, Frodlund M, Zhang Y, Sandner L, Dahle C, Hinkula J, Sjöwall C. SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. Front Immunol 2021;12:724047. [PMID: 34512651 DOI: 10.3389/fimmu.2021.724047] [Reference Citation Analysis]
88 Billy E, Clarot F, Depagne C, Korsia-Meffre S, Rochoy M, Zores F. Thrombotic events after AstraZeneca vaccine: What if it was related to dysfunctional immune response? Therapie 2021;76:367-9. [PMID: 33892936 DOI: 10.1016/j.therap.2021.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Quenzer F, Smyres C, Tabarez N, Singh S, LaFree A, Tomaszewski C, Hayden SR. Large Cerebellar Stroke in a Young COVID-19-Positive Patient: Case Report. J Emerg Med 2021;61:29-36. [PMID: 33863570 DOI: 10.1016/j.jemermed.2021.02.004] [Reference Citation Analysis]
90 Rao RC, Dlouhy BJ, Capell BC, Akeju O. The endangered physician-scientist and COVID-19. Cell Rep Med 2021;2:100190. [PMID: 33521693 DOI: 10.1016/j.xcrm.2021.100190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, Cantaluppi V. Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol 2021. [PMID: 34226718 DOI: 10.1038/s41581-021-00452-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. PLoS Med 2021;18:e1003648. [PMID: 34029337 DOI: 10.1371/journal.pmed.1003648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
93 Trahtemberg U, Rottapel R, Dos Santos CC, Slutsky AS, Baker A, Fritzler MJ. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis 2021;80:1236-40. [PMID: 33903092 DOI: 10.1136/annrheumdis-2021-220206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
94 Lingel H, Meltendorf S, Billing U, Thurm C, Vogel K, Majer C, Prätsch F, Roggenbuck D, Heuft HG, Hachenberg T, Feist E, Reinhold D, Brunner-Weinzierl MC. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun 2021;122:102682. [PMID: 34214763 DOI: 10.1016/j.jaut.2021.102682] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, Dandekar R, Loudermilk RP, Dai Y, Liu F, Hawes IA, Alvarenga BD, Huynh T, McAlpine L, Rahman NT, Geng B, Chiarella J, Goldman-Israelow B, Vogels CBF, Grubaugh ND, Casanovas-Massana A, Phinney BS, Salemi M, Alexander J, Gallego JA, Lencz T, Walsh H, Lucas C, Klein J, Mao T, Oh J, Ring A, Spudich S, Ko AI, Kleinstein SH, DeRisi JL, Iwasaki A, Pleasure SJ, Wilson MR, Farhadian SF. Exploratory neuroimmune profiling identifies CNS-specific alterations in COVID-19 patients with neurological involvement. bioRxiv 2020:2020. [PMID: 32935102 DOI: 10.1101/2020.09.11.293464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
96 Townsend L, Dyer AH, Naughton A, Kiersey R, Holden D, Gardiner M, Dowds J, O'Brien K, Bannan C, Nadarajan P, Dunne J, Martin-Loeches I, Fallon PG, Bergin C, O'Farrelly C, Cheallaigh CN, Bourke NM, Conlon N. Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health. Front Immunol 2021;12:676932. [PMID: 34025675 DOI: 10.3389/fimmu.2021.676932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Kaulen LD, Doubrovinskaia S, Mooshage C, Jordan B, Purrucker J, Haubner C, Seliger C, Lorenz HM, Nagel S, Wildemann B, Bendszus M, Wick W, Schönenberger S. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol 2021. [PMID: 34668274 DOI: 10.1111/ene.15147] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Hosseini P, Fallahi MS, Erabi G, Pakdin M, Zarezadeh SM, Faridzadeh A, Entezari S, Ansari A, Poudineh M, Deravi N. Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities. Front Mol Biosci 2022;9:804109. [DOI: 10.3389/fmolb.2022.804109] [Reference Citation Analysis]
99 Barrantes FJ. The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. Brain Behav Immun Health 2021;14:100251. [PMID: 33842898 DOI: 10.1016/j.bbih.2021.100251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
100 Ariño H, Heartshorne R, Michael BD, Nicholson TR, Vincent A, Pollak TA, Vogrig A. Neuroimmune disorders in COVID-19. J Neurol 2022. [PMID: 35353232 DOI: 10.1007/s00415-022-11050-w] [Reference Citation Analysis]
101 Raza HA, Sen P, Bhatti OA, Gupta L. Sex hormones, autoimmunity and gender disparity in COVID-19. Rheumatol Int 2021;41:1375-86. [PMID: 33903964 DOI: 10.1007/s00296-021-04873-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Haeckel A, Ascher L, Beindorff N, Prasad S, Garczyńska K, Guo J, Schellenberger E. Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications. Apoptosis 2021;26:534-47. [PMID: 34405304 DOI: 10.1007/s10495-021-01686-w] [Reference Citation Analysis]
103 Maier C, Wong A, Woodhouse I, Schneider F, Kulpa D, Silvestri G. Broad Auto-Reactive IgM Responses Are Common In Critically Ill COVID-19 Patients. Res Sq 2020:rs. [PMID: 33398261 DOI: 10.21203/rs.3.rs-128348/v1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Credle JJ, Gunn J, Sangkhapreecha P, Monaco DR, Zheng XA, Tsai HJ, Wilbon A, Morgenlander WR, Dong Y, Jayaraman S, Tosi L, Parekkadan B, Baer AN, Roederer M, Bloch EM, Tobian AAR, Zyskind I, Silverberg JI, Rosenberg AZ, Cox AL, Lloyd T, Mammen AL, Larman HB. Neutralizing IFNL3 Autoantibodies in Severe COVID-19 Identified Using Molecular Indexing of Proteins by Self-Assembly. bioRxiv 2021:2021. [PMID: 33688651 DOI: 10.1101/2021.03.02.432977] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Gasparini G, Canepa P, Verdiani S, Carmisciano L, Cozzani E, De Grazia D, Andrea O, Icardi G, Parodi A. A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients. Int J Immunopathol Pharmacol 2021;35:20587384211042115. [PMID: 34541915 DOI: 10.1177/20587384211042115] [Reference Citation Analysis]
106 Vallone MG, Vazquez C, Chuliber FA, Privitera V, Ferraris A, Cantarella RF, Indo MF, Sanchez Thomas DM, Peuchot VA, Vazquez FJ. Low Incidence of Symptomatic Thrombotic Events in Adult Patients Hospitalized with Coronavirus 19: A Retrospective Cohort Study. Clin Appl Thromb Hemost 2021;27:10760296211051712. [PMID: 34714177 DOI: 10.1177/10760296211051712] [Reference Citation Analysis]
107 Dauby N, Catteau L, Hautekiet J, Montourcy M, Bottieau E, Goetghebeur E, Van Beckhoven D. Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'. Int J Antimicrob Agents 2021;57:106261. [PMID: 33321211 DOI: 10.1016/j.ijantimicag.2020.106261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Schultheiß C, Paschold L, Willscher E, Simnica D, Wöstemeier A, Muscate F, Wass M, Eisenmann S, Dutzmann J, Keyßer G, Gagliani N, Binder M. Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19. iScience 2021;24:103325. [PMID: 34723157 DOI: 10.1016/j.isci.2021.103325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Mangge H, Kneihsl M, Schnedl W, Sendlhofer G, Curcio F, Domenis R. Immune Responses against SARS-CoV-2-Questions and Experiences. Biomedicines 2021;9:1342. [PMID: 34680460 DOI: 10.3390/biomedicines9101342] [Reference Citation Analysis]
110 Sciascia S, Radin M, Bazzan M, Montaruli B, Cosseddu D, Norbiato C, Bertero MT, Carignola R, Bacco B, Gallo Cassarino S, Roccatello D. Antiphospholipid Antibodies and Infection: Non Nova Sed Nove. Front Immunol 2021;12:687534. [PMID: 34220842 DOI: 10.3389/fimmu.2021.687534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, Ben-Yehuda O, Granada JF, Dressler O, Tinuoye EO, Granada C, Bustamante J, Peyra C, Godoy LC, Palacios IF, Fuster V. Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:917-28. [PMID: 35241226 DOI: 10.1016/j.jacc.2021.12.023] [Reference Citation Analysis]
112 Chinnaraj M, Pengo V, Pozzi N. A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis. Front Immunol 2021;12:741589. [PMID: 34567006 DOI: 10.3389/fimmu.2021.741589] [Reference Citation Analysis]
113 Perepu US, Chambers I, Wahab A, Ten Eyck P, Wu C, Dayal S, Sutamtewagul G, Bailey SR, Rosenstein LJ, Lentz SR. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021;19:2225-34. [PMID: 34236768 DOI: 10.1111/jth.15450] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
114 Nappi F, Giacinto O, Ellouze O, Nenna A, Avtaar Singh SS, Chello M, Bouzguenda A, Copie X. Association between COVID-19 Diagnosis and Coronary Artery Thrombosis: A Narrative Review. Biomedicines 2022;10:702. [DOI: 10.3390/biomedicines10030702] [Reference Citation Analysis]
115 Nasonov EL. 2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii arkhiv 2021;93. [DOI: 10.26442/00403660.2021.05.200799] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Hirschenberger M, Hunszinger V, Sparrer KMJ. Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells 2021;10:2134. [PMID: 34440903 DOI: 10.3390/cells10082134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Dauby N, Hautekiet J, Catteau L, Montourcy M, Van Beckhoven D, Bottieau E, Goetghebeur E. Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'". Int J Antimicrob Agents 2021;57:106307. [PMID: 33609720 DOI: 10.1016/j.ijantimicag.2021.106307] [Reference Citation Analysis]
118 Fox SE, Falgout L, Vander Heide RS. COVID-19 myocarditis: quantitative analysis of the inflammatory infiltrate and a proposed mechanism. Cardiovasc Pathol 2021;54:107361. [PMID: 34174415 DOI: 10.1016/j.carpath.2021.107361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Benjamin LA, Paterson RW, Moll R, Pericleous C, Brown R, Mehta PR, Athauda D, Ziff OJ, Heaney J, Checkley AM, Houlihan CF, Chou M, Heslegrave AJ, Chandratheva A, Michael BD, Blennow K, Vivekanandam V, Foulkes A, Mummery CJ, Lunn MP, Keddie S, Spyer MJ, Mckinnon T, Hart M, Carletti F, Jäger HR, Manji H, Zandi MS, Werring DJ, Nastouli E, Simister R, Solomon T, Zetterberg H, Schott JM, Cohen H, Efthymiou M; UCLH Queen Square COVID-19 Biomarker Study group. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. EClinicalMedicine 2021;:101070. [PMID: 34401683 DOI: 10.1016/j.eclinm.2021.101070] [Reference Citation Analysis]
120 Jobe SM, Wen R. Another front in COVID-19's perfect storm. Blood 2021;137:1006-7. [PMID: 33630053 DOI: 10.1182/blood.2020010459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature 2021;590:29-31. [PMID: 33469204 DOI: 10.1038/d41586-021-00149-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
122 Schmaier AA, Pajares Hurtado GM, Manickas-Hill ZJ, Sack KD, Chen SM, Bhambhani V, Quadir J, Nath AK, Collier AY, Ngo D, Barouch DH, Shapiro NI, Gerszten RE, Yu XG, Peters KG, Flaumenhaft R, Parikh SM; MGH COVID-19 Collection and Processing Team. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. JCI Insight 2021;6:e151527. [PMID: 34506304 DOI: 10.1172/jci.insight.151527] [Reference Citation Analysis]
123 Kaklamanos A, Belogiannis K, Skendros P, Gorgoulis VG, Vlachoyiannopoulos PG, Tzioufas AG. COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Front Immunol 2021;12:719023. [PMID: 34512643 DOI: 10.3389/fimmu.2021.719023] [Reference Citation Analysis]
124 Nappi F, Iervolino A, Avtaar Singh SS. Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. Biomedicines 2022;10:437. [DOI: 10.3390/biomedicines10020437] [Reference Citation Analysis]
125 Puhm F, Flamand L, Boilard E. Platelet extracellular vesicles in COVID-19: Potential markers and makers. J Leukoc Biol 2021. [PMID: 34730839 DOI: 10.1002/JLB.3MIR0221-100R] [Reference Citation Analysis]
126 Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, Franke C, Glöckl R, Gogoll C, Hummel T, Kronsbein J, Maibaum T, Peters EMJ, Pfeifer M, Platz T, Pletz M, Pongratz G, Powitz F, Rabe KF, Scheibenbogen C, Stallmach A, Stegbauer M, Wagner HO, Waller C, Wirtz H, Zeiher A, Zwick RH. [S1 Guideline Post-COVID/Long-COVID]. Pneumologie 2021;75:869-900. [PMID: 34474488 DOI: 10.1055/a-1551-9734] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Bertin D, Brodovitch A, Beziane A, Mege JL, Heim X, Bardin N. Reply. Arthritis Rheumatol 2021;73:899-900. [DOI: 10.1002/art.41633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Hingorani KS, Bhadola S, Cervantes-arslanian AM. COVID-19 and the Brain. Trends in Cardiovascular Medicine 2022. [DOI: 10.1016/j.tcm.2022.04.004] [Reference Citation Analysis]
129 Cimolai N. Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19. SN Compr Clin Med 2021;:1-16. [PMID: 34179695 DOI: 10.1007/s42399-021-00992-3] [Reference Citation Analysis]
130 Shi H, Gandhi AA, Smith SA, Wang Q, Chiang D, Yalavarthi S, Ali RA, Liu C, Sule G, Tsou PS, Zuo Y, Kanthi Y, Farkash EA, Lin JD, Morrissey JH, Knight JS. Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. medRxiv 2021:2021. [PMID: 33655266 DOI: 10.1101/2021.02.21.21252160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, Barman L, Bennett K, Chakraborty S, Chang I, Cheung P, Chinthrajah S, Dhingra S, Do E, Finck A, Gaano A, Geßner R, Giannini HM, Gonzalez J, Greib S, Gündisch M, Hsu AR, Kuo A, Manohar M, Mao R, Neeli I, Neubauer A, Oniyide O, Powell AE, Puri R, Renz H, Schapiro JM, Weidenbacher PA, Wittman R, Ahuja N, Chung HR, Jagannathan P, James J, Kim PS, Meyer NJ, Nadeau K, Radic M, Robinson WH, Singh U, Wang TT, Wherry EJ, Skevaki C, Prak ETL, Utz PJ. New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. medRxiv 2021:2021. [PMID: 33532787 DOI: 10.1101/2021.01.27.21250559] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
132 Menter T, Tzankov A, Bruder E. [Impact of SARS-CoV-2/COVID-19 on the placenta]. Pathologe 2021. [PMID: 34115179 DOI: 10.1007/s00292-021-00952-7] [Reference Citation Analysis]
133 Poli V, Pui-Yan Ma V, Di Gioia M, Broggi A, Benamar M, Chen Q, Mazitschek R, Haggarty SJ, Chatila TA, Karp JM, Zanoni I. Zinc-dependent histone deacetylases drive neutrophil extracellular trap formation and potentiate local and systemic inflammation. iScience 2021;24:103256. [PMID: 34761180 DOI: 10.1016/j.isci.2021.103256] [Reference Citation Analysis]
134 Simka M. Is digital necrosis in COVID-19 caused by neutrophil extracellular traps: Potential therapeutic strategies. Med Hypotheses 2021;156:110684. [PMID: 34583310 DOI: 10.1016/j.mehy.2021.110684] [Reference Citation Analysis]
135 Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, Grigoryan L, Trisal M, Edara VV, Lai L, Chang SE, Feng A, Dhingra S, Shah M, Lee AS, Chinthrajah S, Sindher SB, Mallajosyula V, Gao F, Sigal N, Kowli S, Gupta S, Pellegrini K, Tharp G, Maysel-Auslender S, Hamilton S, Aoued H, Hrusovsky K, Roskey M, Bosinger SE, Maecker HT, Boyd SD, Davis MM, Utz PJ, Suthar MS, Khatri P, Nadeau KC, Pulendran B. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 2021. [PMID: 34252919 DOI: 10.1038/s41586-021-03791-x] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
136 Hidalgo A, Libby P, Soehnlein O, Aramburu IV, Papayannopoulos V, Silvestre-Roig C. Neutrophil extracellular traps: from physiology to pathology. Cardiovasc Res 2021:cvab329. [PMID: 34648022 DOI: 10.1093/cvr/cvab329] [Reference Citation Analysis]
137 Verma A, Hawes CE, Lakshmanappa YS, Roh JW, Schmidt BA, Dutra J, Louie W, Liu H, Ma ZM, Watanabe JK, Usachenko JL, Immareddy R, Sammak RL, Pollard R, Reader JR, Olstad KJ, Coffey LL, Kozlowski PA, Hartigan-O'Connor DJ, Nussenzweig M, Van Rompay KKA, Morrison JH, Iyer SS. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. Cell Rep 2021;37:109942. [PMID: 34706272 DOI: 10.1016/j.celrep.2021.109942] [Reference Citation Analysis]
138 Chavda V, Chaurasia B, Fiorindi A, Umana GE, Lu B, Montemurro N. Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities. Neurology International 2022;14:391-405. [DOI: 10.3390/neurolint14020032] [Reference Citation Analysis]
139 Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, Goldman M, Landegren N, Bastard P, Shoenfeld Y, Conrad K. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev 2021;21:103012. [PMID: 34896650 DOI: 10.1016/j.autrev.2021.103012] [Reference Citation Analysis]
140 Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol 2021. [PMID: 34427929 DOI: 10.1002/jmv.27292] [Reference Citation Analysis]
141 Becker K, Beythien G, de Buhr N, Stanelle-Bertram S, Tuku B, Kouassi NM, Beck S, Zickler M, Allnoch L, Gabriel G, von Köckritz-Blickwede M, Baumgärtner W. Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2. Front Immunol 2021;12:640842. [PMID: 33912167 DOI: 10.3389/fimmu.2021.640842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
142 Xie B, Zhang J, Li Y, Yuan S, Shang Y. COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Front Immunol 2020;11:607583. [PMID: 33584679 DOI: 10.3389/fimmu.2020.607583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
143 Al-Gburi S, Beissert S, Günther C. Molecular mechanisms of vasculopathy and coagulopathy in COVID-19. Biol Chem 2021;402:1505-18. [PMID: 34657406 DOI: 10.1515/hsz-2021-0245] [Reference Citation Analysis]
144 Ito T, Kakuuchi M, Maruyama I. Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation. Crit Care 2021;25:95. [PMID: 33685461 DOI: 10.1186/s13054-021-03524-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Gheymati A, Ariannejad H, Hosseini SH, Jamalkhani S, Sholzberg M, Monreal M, Jimenez D, Piazza G, Parikh SA, Kirtane AJ, Eikelboom JW, Connors JM, Hunt BJ, Konstantinides SV, Cushman M, Weitz JI, Stone GW, Krumholz HM, Lip GYH, Goldhaber SZ, Bikdeli B. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:1903-21. [PMID: 33741176 DOI: 10.1016/j.jacc.2021.02.035] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
146 Chen C, Amelia A, Ashdown GW, Mueller I, Coussens AK, Eriksson EM. Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection. Mol Med 2021;27. [DOI: 10.1186/s10020-021-00422-z] [Reference Citation Analysis]
147 Sudhakar M, Winfred SB, Meiyazhagan G, Venkatachalam DP. Mechanisms contributing to adverse outcomes of COVID-19 in obesity. Mol Cell Biochem 2022. [PMID: 35084674 DOI: 10.1007/s11010-022-04356-w] [Reference Citation Analysis]
148 Wolf A, Khimani F, Yoon B, Gerhart C, Endsley D, Ray A, Yango A, Flynn S, H.y. Lip G, Gonzalez S, Sathyamoorthy M. The mechanistic basis linking cytokine storm to thrombosis in COVID-19. Thrombosis Update 2022. [DOI: 10.1016/j.tru.2022.100110] [Reference Citation Analysis]
149 Hohberger B, Mardin CY. OCT Angiography as an Interdisciplinary Diagnostic Tool for Systemic Diseases. Klin Monbl Augenheilkd 2021;238:1294-8. [PMID: 34879428 DOI: 10.1055/a-1654-0504] [Reference Citation Analysis]
150 Steenhuis M, van Mierlo G, Derksen NI, Ooijevaar-de Heer P, Kruithof S, Loeff FL, Berkhout LC, Linty F, Reusken C, Reimerink J, Hogema B, Zaaijer H, van de Watering L, Swaneveld F, van Gils MJ, Bosch BJ, van Ham SM, Ten Brinke A, Vidarsson G, van der Schoot EC, Rispens T. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. Clin Transl Immunology 2021;10:e1285. [PMID: 34026115 DOI: 10.1002/cti2.1285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
151 Rabady S, Altenberger J, Brose M, Denk-Linnert DM, Fertl E, Götzinger F, de la Cruz Gomez Pellin M, Hofbaur B, Hoffmann K, Hoffmann-Dorninger R, Koczulla R, Lammel O, Lamprecht B, Löffler-Ragg J, Müller CA, Poggenburg S, Rittmannsberger H, Sator P, Strenger V, Vonbank K, Wancata J, Weber T, Weber J, Weiss G, Wendler M, Zwick RH. [Guideline S1: Long COVID: Diagnostics and treatment strategies]. Wien Klin Wochenschr 2021;133:237-78. [PMID: 34851455 DOI: 10.1007/s00508-021-01974-0] [Reference Citation Analysis]
152 Garraud O, Lacombe K, Tiberghien P. A look-back at convalescent plasma to treat COVID-19. Transfus Apher Sci 2021;60:103063. [PMID: 33478889 DOI: 10.1016/j.transci.2021.103063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
153 Tang W, Askanase AD, Khalili L, Merrill JT. SARS-CoV-2 vaccines in patients with SLE. Lupus Sci Med 2021;8:e000479. [PMID: 33685998 DOI: 10.1136/lupus-2021-000479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
154 Shanmugasundaram S, Kubiak A, Dar A, Shrinet A, Chauhan N, Haque H, Kumar A, A Shukla P. High incidence of large bore temporary hemodialysis catheter malfunction in patients with COVID-19 related kidney injury. J Vasc Access 2022;:11297298211067332. [PMID: 35000486 DOI: 10.1177/11297298211067332] [Reference Citation Analysis]
155 Pulendran B, Arunachalam PS. Systems biological assessment of human immunity to BNT162b2 mRNA vaccination. Res Sq 2021:rs. [PMID: 34013244 DOI: 10.21203/rs.3.rs-438662/v1] [Reference Citation Analysis]
156 Fernández-Lázaro D, Sánchez-Serrano N, Mielgo-Ayuso J, García-Hernández JL, González-Bernal JJ, Seco-Calvo J. Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic? J Clin Med 2021;10:5799. [PMID: 34945095 DOI: 10.3390/jcm10245799] [Reference Citation Analysis]
157 Strich JR, Kanthi Y. VITT(al) insights into vaccine-related clots. Blood 2021;138:2159-60. [PMID: 34854882 DOI: 10.1182/blood.2021014195] [Reference Citation Analysis]
158 Gawaz A, Guenova E. Microvascular Skin Manifestations Caused by COVID-19. Hamostaseologie 2021;41:387-96. [PMID: 34695855 DOI: 10.1055/a-1581-6899] [Reference Citation Analysis]
159 Nishikawa M, Kanno H, Zhou Y, Xiao TH, Suzuki T, Ibayashi Y, Harmon J, Takizawa S, Hiramatsu K, Nitta N, Kameyama R, Peterson W, Takiguchi J, Shifat-E-Rabbi M, Zhuang Y, Yin X, Rubaiyat AHM, Deng Y, Zhang H, Miyata S, Rohde GK, Iwasaki W, Yatomi Y, Goda K. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun 2021;12:7135. [PMID: 34887400 DOI: 10.1038/s41467-021-27378-2] [Reference Citation Analysis]
160 van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, Kolundzic N, Abdulle AE, van der Voort PH, Olde Rikkert MG, van der Hoeven JG, den Dunnen WF, Hillebrands JL, van Goor H. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol 2021;254:307-31. [PMID: 33586189 DOI: 10.1002/path.5642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
161 Garg M, Maralakunte M, Garg S, Dhooria S, Sehgal I, Bhalla AS, Vijayvergiya R, Grover S, Bhatia V, Jagia P, Bhalla A, Suri V, Goyal M, Agarwal R, Puri GD, Sandhu MS. The Conundrum of 'Long-COVID-19': A Narrative Review. Int J Gen Med 2021;14:2491-506. [PMID: 34163217 DOI: 10.2147/IJGM.S316708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. Am J Hematol 2022;97:119-28. [PMID: 34687462 DOI: 10.1002/ajh.26384] [Reference Citation Analysis]
163 Hoteit L, Deeb AP, Andraska EA, Kaltenmeier C, Yazdani HO, Tohme S, Neal MD, Mota RI. The Pathobiological Basis for Thrombotic Complications in COVID-19: a Review of the Literature. Curr Pathobiol Rep 2021;:1-11. [PMID: 34900401 DOI: 10.1007/s40139-021-00228-y] [Reference Citation Analysis]
164 Foret T, Dufrost V, Salomon Du Mont L, Costa P, Lefevre B, Lacolley P, Regnault V, Zuily S, Wahl D. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep 2021;23:65. [PMID: 34218350 DOI: 10.1007/s11926-021-01029-3] [Reference Citation Analysis]
165 Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the Ageing Immune System. Nat Aging 2021;1:769-82. [PMID: 34746804 DOI: 10.1038/s43587-021-00114-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
166 . Thrombose unter Corona, wir müssen aktiv werden!! Phlebologie 2021;50:158-9. [DOI: 10.1055/a-1381-5636] [Reference Citation Analysis]
167 Wang X, Gkrouzman E, Andrade DCO, Andreoli L, Barbhaiya M, Belmont HM, Branch DW, de Jesús GR, Efthymiou M, Ríos-Garcés R, Gerosa M, El Hasbani G, Knight J, Meroni PL, Pazzola G, Petri M, Rand J, Salmon J, Tektonidou M, Tincani A, Uthman IW, Zuily S, Zuo Y, Lockshin M, Cohen H, Erkan D; APS ACTION. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus 2021;:9612033211062523. [PMID: 34915764 DOI: 10.1177/09612033211062523] [Reference Citation Analysis]
168 Pesce M, Agostoni P, Bøtker HE, Brundel B, Davidson SM, De Caterina R, Ferdinandy P, Girao H, Gyöngyösi M, Hulot JS, Lecour S, Perrino C, Schulz R, Sluijter JPG, Steffens S, Tancevski I, Gollmann-Tepeköylü C, Tschöpe C, van Linthout S, Madonna R. COVID-19 related cardiac complications - from clinical evidences to basic mechanisms. Opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovasc Res 2021:cvab201. [PMID: 34117887 DOI: 10.1093/cvr/cvab201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Ruggeri ZM, Ruf W. Is VITT really a HIT. Nat Immunol 2021;22:1352-3. [PMID: 34686863 DOI: 10.1038/s41590-021-01042-9] [Reference Citation Analysis]
170 Andreano E, Nicastri E, Paciello I, Pileri P, Manganaro N, Piccini G, Manenti A, Pantano E, Kabanova A, Troisi M, Vacca F, Cardamone D, De Santi C, Torres JL, Ozorowski G, Benincasa L, Jang H, Di Genova C, Depau L, Brunetti J, Agrati C, Capobianchi MR, Castilletti C, Emiliozzi A, Fabbiani M, Montagnani F, Bracci L, Sautto G, Ross TM, Montomoli E, Temperton N, Ward AB, Sala C, Ippolito G, Rappuoli R. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell 2021;184:1821-1835.e16. [PMID: 33667349 DOI: 10.1016/j.cell.2021.02.035] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 32.0] [Reference Citation Analysis]
171 Lee A, Nahm CH, Lee JS, Lee MK, Lee KR. Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID-19. J Clin Lab Anal 2021;35:e24004. [PMID: 34608677 DOI: 10.1002/jcla.24004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Williamson J, Black L, Black A, Koduri G, Kelly C. There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia. Ir J Med Sci 2021. [PMID: 33564974 DOI: 10.1007/s11845-021-02545-y] [Reference Citation Analysis]
173 Maecker HT. Immune profiling of COVID-19: preliminary findings and implications for the pandemic. J Immunother Cancer 2021;9:e002550. [PMID: 33963016 DOI: 10.1136/jitc-2021-002550] [Reference Citation Analysis]
174 Cillo AR, Somasundaram A, Shan F, Cardello C, Workman CJ, Kitsios GD, Ruffin A, Kunning S, Lampenfeld C, Onkar S, Grebinoski S, Deshmukh G, Methe B, Liu C, Nambulli S, Andrews L, Duprex WP, Joglekar AV, Benos PV, Ray P, Ray A, McVerry BJ, Zhang Y, Lee JS, Das J, Singh H, Morris A, Bruno TC, Vignali DAA. Bifurcated monocyte states are predictive of mortality in severe COVID-19. bioRxiv 2021:2021. [PMID: 33594364 DOI: 10.1101/2021.02.10.430499] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
175 Kircheis R. Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. Int J Mol Sci 2021;22:10791. [PMID: 34639132 DOI: 10.3390/ijms221910791] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Ballow M, Haga CL. Why Do Some People Develop Serious COVID-19 Disease After Infection, While Others Only Exhibit Mild Symptoms? J Allergy Clin Immunol Pract 2021;9:1442-8. [PMID: 33486141 DOI: 10.1016/j.jaip.2021.01.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
177 Mavromanoli AC, Barco S, Konstantinides SV. Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition. Res Pract Thromb Haemost 2021;5. [PMID: 34027284 DOI: 10.1002/rth2.12509] [Reference Citation Analysis]
178 Jiang Y, Duffy F, Hadlock J, Raappana A, Styrchak S, Beck I, Mast FD, Miller LR, Chour W, Houck J, Armistead B, Duvvuri VR, Yeung W, Haglund M, Wallner J, Wallick JA, Hardy S, Oldroyd A, Ko D, Gervassi A, Murray KM, Kaplan H, Aitchison JD, Heath JR, Sather DN, Goldman JD, Frenkel L, Harrington WE. Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. PLoS One 2021;16:e0259902. [PMID: 34788328 DOI: 10.1371/journal.pone.0259902] [Reference Citation Analysis]
179 Lim MS, Mcrae S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Crit Rev Oncol Hematol 2021;168:103529. [PMID: 34800652 DOI: 10.1016/j.critrevonc.2021.103529] [Reference Citation Analysis]
180 Jarai BM, Stillman Z, Bomb K, Kloxin AM, Fromen CA. Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. ACS Biomater Sci Eng 2021;7:1742-64. [PMID: 33356134 DOI: 10.1021/acsbiomaterials.0c01287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
181 Root-Bernstein R. COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-binding proteins, platelet factor 4, prothrombin, and coagulation factors. Bioessays 2021;43:e2100158. [PMID: 34677872 DOI: 10.1002/bies.202100158] [Reference Citation Analysis]
182 Hernández-Huerta MT, Pérez-Santiago AD, Pérez-Campos Mayoral L, Sánchez Navarro LM, Rodal Canales FJ, Majluf-Cruz A, Matias-Cervantes CA, Pérez-Campos Mayoral E, Romero Díaz C, Mayoral-Andrade G, Martínez Cruz M, Luna Ángel J, Pérez-Campos E. Mechanisms of Immunothrombosis by SARS-CoV-2. Biomolecules 2021;11:1550. [PMID: 34827548 DOI: 10.3390/biom11111550] [Reference Citation Analysis]
183 Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861-80. [PMID: 33497610 DOI: 10.1016/j.cell.2021.01.007] [Cited by in Crossref: 172] [Cited by in F6Publishing: 178] [Article Influence: 172.0] [Reference Citation Analysis]
184 Go AS, Reynolds K, Tabada GH, Prasad PA, Sung SH, Garcia E, Portugal C, Fan D, Pai AP, Fang MC. COVID-19 and Risk of VTE in Ethnically Diverse Populations. Chest 2021:S0012-3692(21)01353-2. [PMID: 34293316 DOI: 10.1016/j.chest.2021.07.025] [Reference Citation Analysis]
185 Carvalho V, Pinho D, Lima RA, Teixeira JC, Teixeira S. Blood Flow Modeling in Coronary Arteries: A Review. Fluids 2021;6:53. [DOI: 10.3390/fluids6020053] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
186 Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. Mayo Clin Proc 2021;96:989-1005. [PMID: 33714595 DOI: 10.1016/j.mayocp.2021.01.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
187 Schmaier AA, Hurtado GP, Manickas-Hill ZJ, Sack KD, Chen SM, Bhambhani V, Quadir J, Nath AK, Collier AY, Ngo D, Barouch DH, Gerszten RE, Yu XG, Peters K, Flaumenhaft R, Parikh SM; MGH COVID-19 Collection and Processing Team. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. medRxiv 2021:2021. [PMID: 34031665 DOI: 10.1101/2021.05.13.21257070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
188 Fedorchenko Y, Zimba O. CYTOKINES AS POTENTIAL MARKERS OF COVID-19 SEVERITY AND OUTCOMES. CAJMHE 2022;3:10-20. [DOI: 10.47316/cajmhe.2022.3.1.01] [Reference Citation Analysis]
189 Groarke EM, Dulau-Florea AE, Kanthi Y. Thrombotic manifestations of VEXAS syndrome. Semin Hematol 2021;58:230-8. [PMID: 34802545 DOI: 10.1053/j.seminhematol.2021.10.006] [Reference Citation Analysis]
190 Shaw BC, Maglinger GB, Ujas T, Rupareliya C, Fraser JF, Grupke S, Kesler M, Gelderblom M, Pennypacker KR, Turchan-Cholewo J, Stowe AM. Isolation and identification of leukocyte populations in intracranial blood collected during mechanical thrombectomy. J Cereb Blood Flow Metab 2021;:271678X211028496. [PMID: 34250820 DOI: 10.1177/0271678X211028496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL, Aschenbrenner AC. Neutrophils in COVID-19. Front Immunol 2021;12:652470. [PMID: 33841435 DOI: 10.3389/fimmu.2021.652470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
192 Kumar A, Narayan RK, Prasoon P, Kumari C, Kaur G, Kumar S, Kulandhasamy M, Sesham K, Pareek V, Faiq MA, Pandey SN, Singh HN, Kant K, Shekhawat PS, Raza K, Kumar S. COVID-19 Mechanisms in the Human Body-What We Know So Far. Front Immunol 2021;12:693938. [PMID: 34790191 DOI: 10.3389/fimmu.2021.693938] [Reference Citation Analysis]
193 Boyd S, Martin-Loeches I. The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients. Ir J Med Sci 2021. [PMID: 33415688 DOI: 10.1007/s11845-020-02503-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 2021;40:2611-9. [PMID: 33733315 DOI: 10.1007/s10067-021-05691-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
195 Subramaniam S, Ruf W, Bosmann M. Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019. Br J Pharmacol 2021. [PMID: 34235728 DOI: 10.1111/bph.15587] [Reference Citation Analysis]
196 Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, Dandekar R, Loudermilk RP, Dai Y, Liu F, Sunshine S, Liu J, Wu W, Hawes IA, Alvarenga BD, Huynh T, McAlpine L, Rahman NT, Geng B, Chiarella J, Goldman-Israelow B, Vogels CBF, Grubaugh ND, Casanovas-Massana A, Phinney BS, Salemi M, Alexander JR, Gallego JA, Lencz T, Walsh H, Wapniarski AE, Mohanty S, Lucas C, Klein J, Mao T, Oh J, Ring A, Spudich S, Ko AI, Kleinstein SH, Pak J, DeRisi JL, Iwasaki A, Pleasure SJ, Wilson MR, Farhadian SF. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2021;2:100288. [PMID: 33969321 DOI: 10.1016/j.xcrm.2021.100288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
197 Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med 2022;28:911-23. [PMID: 35585196 DOI: 10.1038/s41591-022-01810-6] [Reference Citation Analysis]
198 Hoepel W, Chen HJ, Geyer CE, Allahverdiyeva S, Manz XD, de Taeye SW, Aman J, Mes L, Steenhuis M, Griffith GR, Bonta PI, Brouwer PJM, Caniels TG, van der Straten K, Golebski K, Jonkers RE, Larsen MD, Linty F, Nouta J, van Roomen CPAA, van Baarle FEHP, van Drunen CM, Wolbink G, Vlaar APJ, de Bree GJ, Sanders RW, Willemsen L, Neele AE, van de Beek D, Rispens T, Wuhrer M, Bogaard HJ, van Gils MJ, Vidarsson G, de Winther M, den Dunnen J. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med 2021;13:eabf8654. [PMID: 33979301 DOI: 10.1126/scitranslmed.abf8654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
199 Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J 2022:S0002-8703(21)00483-X. [PMID: 34986394 DOI: 10.1016/j.ahj.2021.12.010] [Reference Citation Analysis]
200 Calabrese L, Winthrop KL. Rheumatology and COVID-19 at 1 year: facing the unknowns. Ann Rheum Dis 2021:annrheumdis-2021-219957. [PMID: 33658236 DOI: 10.1136/annrheumdis-2021-219957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
201 Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Chew NW, Cleary SJ, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Im KW, Serwas NK, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S, Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF; UCSF COMET Consortium. Global absence and targeting of protective immune states in severe COVID-19. Nature 2021;591:124-30. [PMID: 33494096 DOI: 10.1038/s41586-021-03234-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 47.0] [Reference Citation Analysis]
202 Ratto N, Bouchnita A, Chelle P, Marion M, Panteleev M, Nechipurenko D, Tardy-Poncet B, Volpert V. Patient-Specific Modelling of Blood Coagulation. Bull Math Biol 2021;83:50. [PMID: 33772645 DOI: 10.1007/s11538-021-00890-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]